drugset

drugset / Trial / NCT00393965

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

NCT00393965 ↗

Phase 1 Completed 18 enrolled Myrexis Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

Timeline

Start: 2005-12
Primary completion: 2007-08
Completion: 2008-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Verubulin	Small molecule	—	Intravenous

Indications